An evaluation of the mechanism of scopolamine-induced impairment in two passive avoidance protocols

https://doi.org/10.1016/0091-3057(88)90267-5Get rights and content

Abstract

The effects of several doses of the centrally-acting muscarinic antagonist, scopolamine, on subsequent learning and memory were examined using two versions of a standard light versus dark passive avoidance paradigm. The first protocol was employed primarily to examine the effects of scopolamine on the acquisition component of learning and memory as subject performance was measured during five successive (repeated) training trials. The second protocol employed a one-trial twenty-four hour retention task in which subjects were given one training trial followed by one testing trial twenty-four hours later. This latter test emcompasses acquisition, retention, and recall components of learning and memory. Dose response studies indicated an effective dose range of 0.4–1.2 mg/kg with 0.8 mg/kg producing maximal performance decrement. Differential scopolamine treatment demonstrated that the drug's primary effect was on the acquisition component only under the present experimental protocols. Furthermore, scopolamine was not found to produce state-dependent learning. Animals administered scopolamine before training and testing failed to perform better than animals receiving pre-training administration only.

References (49)

  • J. Watts et al.

    Effects of scopolamine on radial maze performance in rats

    Physiol Behav

    (1981)
  • N.I. Wiener et al.

    Scopolamine-induced impairment of long-term retention in rats

    Behav Biol

    (1973)
  • W.W. Beatty et al.

    Scopolamine impairs encoding and retrieval of spatial working memory in rats

    Physiol Psychol

    (1986)
  • W.W. Beatty et al.

    Patterns of memory failure after scopolamine treatment: implications for cholinergic hypothesis of dementia

    Behav Neurol Biol

    (1986)
  • D. Berger et al.

    An analysis of the learning deficits produced by scopolamine

    Psychopharmacologia

    (1969)
  • D. Berger et al.

    Asymmetrical dissociation of learning between scopolamine and WY 4056, a new benzodiazepine tranquilizer

    Psychopharmacologia

    (1969)
  • J.J. Buccafusco et al.

    Brain neurotransmitters and the development and maintenance of experimental hypertension

    Prog Drug Res

    (1986)
  • W. Calhoun et al.

    Effects of scopolamine on acquisition of passive avoidance

    Psychopharmacologia

    (1968)
  • E. Caine et al.

    Qualitative analysis of scopolamine-induced amnesia

    Psychopharmacology (Berlin)

    (1981)
  • L. Chiapetta et al.

    Comparison of learning impairment and activity depression produced by two classes of cholinergic blocking agents

    Arch Int Pharmacodyn

    (1969)
  • T.J. Crow et al.

    An analysis of the learning deficit following hyoscine administration to man

    Br J Pharmacol

    (1973)
  • S.L. Dilts et al.

    Effect of cholinergic drugs on passive avoidance in the mouse

    J Pharmacol Exp Ther

    (1967)
  • F.R. Domer et al.

    Investigations of the amnesic properties of scopolamine and related compounds

    Arch Int Pharmacodyn Ther

    (1960)
  • E.F. Domino et al.

    Effects of reticular stimulation, d-amphetamine and scopolamine on acetylcholine release from the hippocampus of brainstem transected cats

    Arch Int Pharmacodyn Ther

    (1977)
  • Cited by (98)

    • What animal models can tell us about long-term cognitive dysfunction following sepsis: A systematic review

      2021, Neuroscience and Biobehavioral Reviews
      Citation Excerpt :

      The shortest protocol for an inhibitory avoidance test therefore comprises of two trials: a single acquisition trial, followed by a single retention trial generally run 24 h later (Bartus et al., 1980; Bohdanecký and Jarvik, 1967; Jarvik and Kopp, 1967). The downside of this protocol is the large inter-individual variability of responses, which implies that a fairly large sample size is usually required to obtain statistically meaningful information (Elrod and Buccafusco, 1988; Lamberty and Gower, 1990). Other commonly used protocols are the multiple-trial acquisition protocols, in which acquisition trials are run either successively or with a 24-h inter-trial interval, and in which a single retention trial is run on the last day of testing (Graham and Buccafusco, 2001; Ray and Nagy, 1978).

    • Alkaloid chemodiversity in Mandragora spp. is associated with loss-of-functionality of MoH6H, a hyoscyamine 6β-hydroxylase gene

      2019, Plant Science
      Citation Excerpt :

      Scopolamine differs from hyoscyamine by the presence of an epoxide bridge present in the tropane ring of scopolamine (Fig. 1) [1]. Both alkaloids have comparable pharmacological action and compete with acetylcholine for the muscarinic site of the parasympathetic nervous system, thus preventing the passage of nerve impulses [2]. The agonist properties of hyoscyamine and scopolamine give rise to several important pharmacological effects, such as antispasmodic actions on the gastrointestinal tract and anti-secretory effects controlling salivary secretions during surgical operations.

    • Obestatin improves oxidative brain damage and memory dysfunction in rats induced with an epileptic seizure

      2017, Peptides
      Citation Excerpt :

      On the 71st h of PTZ or saline (control group) injection, the rats were again placed in the illuminated compartment to evaluate the passive avoidance response. Based on the previous reports [22], the rats that have avoided entering the dark chamber with a latency over 300 s were considered to have normal learning and memory performance, while a shorter latency to enter the dark chamber was regarded as memory dysfunction. Brain tissues were homogenized with ice-cold trichloroacetic acid (10% per 1 g tissue) with Ultra Turrax tissue homogenizer.

    View all citing articles on Scopus
    View full text